Patents by Inventor Melanie Desbois

Melanie Desbois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYTOKINE DERIVED TREATMENT WITH REDUCED VASCULAR LEAK SYNDROME
    Publication number: 20230183306
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an IL-15 derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 29, 2022
    Publication date: June 15, 2023
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • Cytokine derived treatment with reduced vascular leak syndrome
    Patent number: 11401312
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 2, 2022
    Assignees: Cytune Pharma, Institut Gustave Roussy (IGR)
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • COMBINED PHARMACEUTICAL COMPOSITION
    Publication number: 20220202904
    Abstract: The present invention relates to a combined pharmaceutical composition, adapted for simultaneous, separate, or sequential administration for treating cancer in a subject comprising (a) a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15R? or derivatives thereof; a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and (b) an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof, a polynucleotide coding therefore, or a vector comprising such a polynucleotide.
    Type: Application
    Filed: March 15, 2022
    Publication date: June 30, 2022
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • COMBINED PHARMACEUTICAL COMPOSITION
    Publication number: 20220168395
    Abstract: The present disclosure relates to a combined pharmaceutical composition, adapted for simultaneous, separate, or sequential administration for treating cancer in a subject comprising (a) a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Ra or derivatives thereof; a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and (b) an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof, a polynucleotide coding therefore, or a vector comprising such a polynucleotide.
    Type: Application
    Filed: February 22, 2022
    Publication date: June 2, 2022
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • COMBINED PHARMACEUTICAL COMPOSITION
    Publication number: 20160184399
    Abstract: The present disclosure relates to a combined pharmaceutical composition, adapted for simultaneous, separate, or sequential administration for treating cancer in a subject comprising (a) a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Ra or derivatives thereof; a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and (b) an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof, a polynucleotide coding therefore, or a vector comprising such a polynucleotide.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: David BECHARD, Nathalie CHAPUT, Melanie DESBOIS
  • CYTOKINE DERIVED TREATMENT WITH REDUCED VASCULAR LEAK SYNDROME
    Publication number: 20160068584
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an IL-15 derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 22, 2014
    Publication date: March 10, 2016
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois